| 1.42 -0.1 (-6.58%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.2 | 1-year : | 2.62 |
| Resists | First : | 1.89 | Second : | 2.25 |
| Pivot price | 1.7  |
|||
| Supports | First : | 1.3 | Second : | 1.08 |
| MAs | MA(5) : | 1.54 |
MA(20) : | 1.72 |
| MA(100) : | 1.28  |
MA(250) : | 1.19 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 10.3 |
D(3) : | 13.9 |
| RSI | RSI(14): 39.5 |
|||
| 52-week | High : | 2.32 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ NRSN ] has closed above bottom band by 8.8%. Bollinger Bands are 6.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.55 |
| Low: | 1.3 - 1.31 | 1.31 - 1.32 |
| Close: | 1.4 - 1.42 | 1.42 - 1.44 |
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Thu, 18 Apr 2024
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at ... - PR Newswire
Fri, 12 Apr 2024
NeuroSense Launches Pre-Funded Warrants Offering - TipRanks.com - TipRanks
Fri, 12 Apr 2024
NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 - PR Newswire
Thu, 11 Apr 2024
NeuroSense Advances ALS Therapy with Promising Trials - TipRanks.com - TipRanks
Wed, 10 Apr 2024
NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement - PR Newswire
Fri, 05 Apr 2024
NeuroSense Announces Year End 2023 Financial Results and Provides Business Update - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 28 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 64 (K) |
| Shares Short P.Month | 211 (K) |
| EPS | -0.83 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -152.8 % |
| Return on Equity (ttm) | -602.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.86 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | -4 (M) |
| PE Ratio | -1.72 |
| PEG Ratio | 0 |
| Price to Book value | -11.84 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.63 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|